EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Minimally Invasive, Extracellular Vesicle-Based Approach for Monitoring Measurable Residual Disease in Acute Myeloid Leukemia: A Proof-of-Concept Study

Helena Branco iD, Joana Carreira iD, Inês Soure iD, Cristina P R Xavier iD, Andreia Rosário iD, Maria Amorim iD, Hugo Osório iD, José E Guimarães, Ana Bela Sarmento-Ribeiro iD, Manuel A Sobrinho-Simões iD, Hugo R Caires iD, M Helena Vasconcelos iD

Cells · 11.06.2026 · 15 (12) · 1068

DOI: 10.3390/cells15121068 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 11.06.2026. Verfasst von Helena Branco und 11 weiteren Autor:innen. Beteiligte Einrichtung: i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Extracellular Vesicles, Neoplasm, Residual. Die Arbeit nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Science and Technology, Fundação para a Ciência e Tecnologia, European Regional Development Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Measurable residual disease (MRD) in acute myeloid leukemia (AML) is monitored through detection of leukemia-associated phenotypic protein markers (LAPMs) in bone marrow aspirates, hindering disease real-time monitoring. We explored peripheral blood (PB), extracellular vesicle (EV)-based methods for MRD monitoring. To confirm that LAPMs are present in AML-derived EVs, EVs were isolated from OCI-AML3 cells by differential centrifugation and characterized according to their size (nanoparticle tracking analysis), morphology (transmission electron microscopy) and protein cargo (proteomic analysis and Western blot). CD14 and CD33 were detected in OCI-AML3 cells and their released EVs. To select a method to isolate EVs from the PB of AML patients, three techniques were tested: size exclusion chromatography followed by ultrafiltration (SEC-UF), Total Exosome Isolation Kit (Invitrogen) and Exo-spin™ Exosome Purification Kit (Cell Guidance Systems). SEC-UF allowed EV isolation with higher purity and less aggregates than the other techniques. LAPMs were detected in those EVs, but their presence depended on the isolation method. Finally, EVs from seven AML patients’ plasma were isolated by SEC-UF. LAPMs were identified in paired samples at diagnosis and remission, with differential expression throughout disease evolution. This proof-of-concept study highlights the possibility of real-time MRD monitoring through LAPMs’ analysis in AML patient’s circulating EVs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Myeloid, AcuteExtracellular VesiclesNeoplasm, ResidualHumansFemaleProof of Concept StudyCell Line, TumorBiomarkers, TumorMaleProteomicsSialic Acid Binding Ig-like Lectin 3Middle AgedAdultLipopolysaccharide Receptors

Stichwörter der Autor:innen

acute myeloid leukemiaextracellular vesiclesliquid biopsiesmeasurable residual disease

Substanzen

Biomarkers, TumorSialic Acid Binding Ig-like Lectin 3Lipopolysaccharide Receptors

Autor:innen und Institutionen

  • i3S-Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal.
  • Cancer Drug Resistance Group, IPATIMUP-Institute of Molecular Pathology and Immunology, University of Porto, Rua Júlio Amaral de Carvalho 45, 4200-135 Porto, Portugal.
  • Laboratório de Oncobiologia e Hematologia, Clinica Universitária de Hematologia, FMUC-Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal.
  • Department of Chemistry, University of Aveiro, Campus Universitário de Santiago, 3810-193 Aveiro, Portugal.
  • Associate Laboratory i4HB-Institute for Health and Bioeconomy, University Institute of Health Sciences-CESPU, 4585-116 Gandra, Portugal.
  • UCIBIO-Applied Molecular Biosciences Unit, Toxicologic Pathology Research Laboratory, University Institute of Health Sciences (1H-TOXRUN, IUCS-CESPU), 4585-116 Gandra, Portugal.

ORCID-Profile: Helena Branco, Joana Carreira, Inês Soure, Cristina P R Xavier, Andreia Rosário, Maria Amorim, Hugo Osório, Ana Bela Sarmento-Ribeiro, Manuel A Sobrinho-Simões, Hugo R Caires, M Helena Vasconcelos

Förderung

  • Foundation for Science and Technology
  • Fundação para a Ciência e Tecnologia
  • European Regional Development Fund
  • COST
  • FCT

Zitieren

APA

Branco, H., Carreira, J., Soure, I., Xavier, C. P. R., Rosário, A., Amorim, M., Osório, H., Guimarães, J. E., Sarmento-Ribeiro, A. B., Sobrinho-Simões, M. A., Caires, H. R., & Vasconcelos, M. H. (2026). A Minimally Invasive, Extracellular Vesicle-Based Approach for Monitoring Measurable Residual Disease in Acute Myeloid Leukemia: A Proof-of-Concept Study. Cells, 15(12), 1068. https://doi.org/10.3390/cells15121068

Vancouver

Branco H, Carreira J, Soure I, Xavier CPR, Rosário A, Amorim M, et al. A Minimally Invasive, Extracellular Vesicle-Based Approach for Monitoring Measurable Residual Disease in Acute Myeloid Leukemia: A Proof-of-Concept Study. Cells. 2026;15(12):1068. doi:10.3390/cells15121068

BibTeX
@article{Branco2026,
  author = {Branco, Helena and Carreira, Joana and Soure, Inês and Xavier, Cristina P R and Rosário, Andreia and Amorim, Maria and Osório, Hugo and Guimarães, José E and Sarmento-Ribeiro, Ana Bela and Sobrinho-Simões, Manuel A and Caires, Hugo R and Vasconcelos, M Helena},
  title = {A Minimally Invasive, Extracellular Vesicle-Based Approach for Monitoring Measurable Residual Disease in Acute Myeloid Leukemia: A Proof-of-Concept Study},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {1068},
  doi = {10.3390/cells15121068}
}
Kostenlos starten →